Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. The company has built a cystic fibrosis (CF) empire, bringing in billions of dollars in revenue annually, and now is ...

Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device, after clinical trial data showed the treatment did not ...

Vertex (VERX) announced the expansion of its Chief Strategy Office with the addition of Christopher Hall and Kathya Capote Peimbert. Their ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $502.55, marking a +0.45% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.33%.

Vertex Solutions, a small business known for the manufacturing of systems integration and advanced training technologies, has ...

Vertex Inc. (NASDAQ: VERX) has expanded its Chief Strategy Office with the addition of Christopher Hall and Kathya Capote ...

derives from Vertex’ near $1 billion acquisition of Semma in 2019, and has started enrolling patients in a phase 1/2 study in the US. The therapy takes the form of stem cell-derived human ...

Despite US President Donald Trump’s unpredictable tariff plans and his desire to revive American manufacturing, overseas expansion by Chinese enterprises will hinge on long-term economic ...

The model, Gemini 2.5 Flash, will soon launch in Vertex AI, Google’s AI development platform. The company says it offers “dynamic and controllable” computing, allowing developers to adjust ...

Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection caught from animals that has a fatality rate of between 40% and 70%, developed by mRNA ...